Danaher has struck a $10 billion deal to acquire Masimo, the medical-device maker known for its pulse oximetry technology. The acquisition, which was announced Monday, will see Masimo operate as a stand-alone company within Danaher's Diagnostics segment. This strategic move expands Danaher's portfolio in the healthcare technology space.

Masimo's innovative patient monitoring solutions have made it a leader in the medical-device industry. The company's technology is widely used in hospitals and healthcare settings worldwide. Danaher's Diagnostics segment already includes several prominent medical technology brands, and adding Masimo strengthens its position in this competitive market.

The acquisition is expected to close in the first half of 2025, subject to regulatory approvals and other customary closing conditions. Danaher plans to finance the deal through a combination of cash and debt. This acquisition represents one of the largest in Danaher's history and demonstrates the company's commitment to expanding its healthcare offerings.